Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Alumis in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($1.48) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis’ Q3 2025 earnings at ($1.38) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.46) EPS, FY2026 earnings at ($5.19) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($2.04) EPS.

Other equities analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Alumis in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Finally, Oppenheimer started coverage on Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $26.00.

Alumis Stock Down 4.5 %

Shares of ALMS opened at $4.70 on Wednesday. Alumis has a 1 year low of $3.18 and a 1 year high of $13.53. The business’s 50 day simple moving average is $5.43 and its 200-day simple moving average is $8.38.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Foresite Capital Management VI LLC bought a new stake in shares of Alumis during the 4th quarter worth approximately $33,033,000. Samsara BioCapital LLC bought a new stake in shares of Alumis during the third quarter worth $34,886,000. Geode Capital Management LLC purchased a new stake in shares of Alumis during the third quarter valued at $3,266,000. Norges Bank bought a new position in shares of Alumis in the fourth quarter worth about $1,606,000. Finally, Foresite Capital Management V LLC increased its stake in Alumis by 3.5% in the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after buying an additional 194,459 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.